首页> 外文期刊>European review for medical and pharmacological sciences. >Long non-coding RNA LINP1 functions as an oncogene in endometrial cancer progression by regulating the PI3K/AKT signaling pathway
【24h】

Long non-coding RNA LINP1 functions as an oncogene in endometrial cancer progression by regulating the PI3K/AKT signaling pathway

机译:通过调节PI3K / AKT信号通路,长期非编码RNA LINP1用作子宫内膜癌进展中的癌基因

获取原文
获取外文期刊封面目录资料

摘要

OBJECTIVE: Endometrial cancer (EC) accounts for about 6% of new cancer cases in female and about 3% of cancer-related deaths were caused by EC. The poor prognosis is mainly due to the distant spread and poor differentiation. In the current study, we want to figure out the role of long non-coding RNA (LncRNA) LINP1 in EC progression. PATIENTS AND METHODS: The quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) assay was involved to access the expression level of LINP1 in EC cell lines and tissues. The Cell Counting Kit-8 (CCK-8) assay, colony formation assay, transwell and Matrigel assay were recruited to figure out the ability of LINP1 in cell proliferation and metastasis in EC. Subsequently, Western blotting was used to detect the expression level of PI3K/AKT in EC. Besides, we used the tumor formation assay in vivo to examine the ability of LINP1 in tumor formation in vivo. RESULTS: LINP1 was proved to be up-regulated in EC cell lines and tissues by qRT-PCR assay. CCK-8 assay and colony formation assay were conducted and the results indicated that LINP1 over-expression can promote cell proliferation in EC in vitro. The data of transwell and Matrigel assays indicated that up-regulated LINP1 can facilitate cell migration and invasion. The results of Western blotting validated that LINP1 can activate PI3K/AKT signaling. Besides, the tumor formation assay verified that LINP1 can promote tumor formation in vivo. CONCLUSIONS: Our research validated that LINP1 served as an oncogenic role in EC progression. The PI3K/AKT signaling pathway might be the underlying mechanism of EC progression. We hope our study can provide novel treatment targets and biomarkers in EC development and progression.
机译:目的:子宫内膜癌(EC)占女性新癌症病例的6%,患有约3%的癌症相关死亡是由EC引起的。预后差主要是由于远距离蔓延和分化差。在目前的研究中,我们希望弄清楚长期非编码RNA(LNCRNA)LINP1在EC进展中的作用。患者和方法:涉及定量实时 - 聚合酶链反应(QRT-PCR)测定方法进入欧共系统细胞系和组织中LINP1的表达水平。募集了细胞计数试剂盒-8(CCK-8)测定,菌落形成测定,Transwell和Matrigel测定,以确定LINP1在EC中细胞增殖和转移的能力。随后,使用蛋白质印迹来检测EC中PI3K / AKT的表达水平。此外,我们在体内使用肿瘤形成测定以检测LINP1在体内肿瘤形成中的能力。结果:通过QRT-PCR测定证明LINP1在EC细胞系和组织中上调。进行CCK-8测定和菌落形成测定,结果表明LINP1过表达可以在体外促进EC的细胞增殖。 Transwell和Matrigel测定的数据表明上调的LINP1可以促进细胞迁移和侵袭。 Western Blotting的结果验证了LINP1可以激活PI3K / AKT信号传导。此外,肿瘤形成测定证实LINP1可以促进体内肿瘤形成。结论:我们的研究经过验证,LINP1在EC进展中担任致癌作用。 PI3K / AKT信号通路可能是EC进展的基本机制。我们希望我们的研究可以在EC开发和进展中提供新的治疗目标和生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号